Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...
New service ensures rapid delivery of small volume clinical trial materials, solving a critical bottleneck in drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback